Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

Esalatmanesh, K. and Jamali, R. and Jamali, A. and Jamali, B. and Nikbakht, M. (2012) Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis. Rheumatology International, 32 (12). pp. 3799-3805.

Full text not available from this repository.
Official URL:


To define the relationship between serum anticyclic citrullinated peptide antibodies (anti-CCP) and disease activity, and to construct a new disease activity index by using anti-CCP in rheumatoid arthritis (RA). One hundred and five RA patients were included. Disease activity based on DAS28-ESR and serum anti-CCP was measured. There was correlation between serum anti-CCP and DAS28-ESR. (R2 = 0.71, P value<0.01). New disease activity index was developed by replacing anti-CCP with ESR in DAS28-ESR. There was correlation between new model and DAS28-ESR. (R2 = 0.91, P value<0.01) The new composite index best cut-off values corresponding to DAS28-ESR values of 2.6, 3.2, and 5.1 were 3.21, 3.38, and 4.74, respectively. There was agreement between new model and DAS28-ESR for determination of patients in different disease activity categories. (Kappa = 0.71, P value<0.01). The new disease activity index that applies serum anti-CCP may predict disease activity in RA. © Springer-Verlag 2011.

Item Type: Article
Additional Information: cited By 3
Uncontrolled Keywords: biological marker; cyclic citrullinated peptide antibody, adult; article; blood level; disease activity; female; human; major clinical study; male; predictive value; priority journal; rheumatoid arthritis, Adult; Aged; Arthritis, Rheumatoid; Autoantibodies; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Pain Measurement; Peptides, Cyclic; Predictive Value of Tests; Severity of Illness Index
Subjects: Medicine
Divisions: Faculty of Medicine > Clinical Sciences > Department of Internal Medicine
Depositing User: editor . 2
Date Deposited: 01 Mar 2017 11:08
Last Modified: 01 Mar 2017 11:08

Actions (login required)

View Item View Item